Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma
NCT04072679
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG:
Sintilimab+IBI305
Sponsor
Chinese Academy of Medical Sciences